Canopy Growth Corporation (CGC) Investment Analysis (1–3 Years)
Executive Summary
Canopy Growth Corporation (NASDAQ: CGC) is one of the most recognized players in the global cannabis industry, having experienced a dramatic rollercoaster ride over the past years. The stock peaked during the 2018 cannabis mania, only to lose over 99% of its value by now, reflecting sector-wide challenges and Canopy's financial struggles. This report offers an in-depth investment analysis for CGC over a 1–3 year timeframe, aimed at a risk-tolerant investor. The analysis is structured into four parts: fundamentals (financials, growth potential, management, industry environment), technical outlook (price charts, support-resistance levels, indicators), peer comparison, and price forecast (market sentiment and analysts' targets). Despite extreme risk, Canopy may offer significant upside under favorable conditions, making a deep understanding essential before any investment decision.
1. Fundamental Analysis
Financial Performance
In FY2024 (April 2023–March 2024), Canopy Growth reported revenue of CAD 297.1 million, an 11% YoY decline from CAD 333.3 million. However, net losses narrowed sharply: FY2024 net loss from continuing operations was CAD 483.7 million, compared to a staggering CAD 3.08 billion in FY2023. Total net loss attributable to shareholders stood at CAD 657.3 million, significantly improved from CAD 3.28 billion the year prior. Cost-cutting measures and the closure of unprofitable segments drove this turnaround, with the gross margin rising to 27%, up by 4600 basis points.
Operating loss in FY2024 was approximately CAD 229 million, while adjusted EBITDA loss dropped to CAD 59 million, a 72% improvement YoY. Cash reserves stood at CAD 203 million as of March 31, 2024, down from CAD 667 million the year before, indicating ongoing cash burn. The company refinanced debt proactively: no significant debt maturities until March 2026, after repaying a USD 100M term loan early.
Quarterly results in FY2024 showed progressive improvement: in Q3 (Oct–Dec 2024), operating loss was just CAD 24 million (down 61% YoY), and adjusted EBITDA loss was only CAD 3 million, nearing breakeven. Free cash flow in the quarter was -CAD 28 million, a 17% YoY improvement.
Despite reduced losses, Canopy remains unprofitable with negative operating and free cash flow. It also launched a USD 200 million ATM equity program in 2025, indicating potential shareholder dilution. However, the company completed its impairment phase, and asset write-downs in FY2024 were limited to CAD 66 million.
Growth Potential
Canopy has shifted focus from low-margin Canadian recreational cannabis to higher-margin medical cannabis, international markets, and vaporizer devices (via Storz & Bickel). In FY2024, Canadian medical cannabis revenue rose 10% to CAD 61 million, while the recreational segment declined. Storz & Bickel revenue grew 43% YoY in Q4.
International medical cannabis revenue grew 6% to CAD 41 million, driven by markets such as Australia, Germany, Poland, and the UK. The PEACE NATURALS brand became the leading cannabis brand in Israel.
The biggest growth opportunity lies in the U.S. market. Canopy cannot directly operate THC-based businesses in the U.S. due to federal prohibition, but it created Canopy USA, LLC, which holds acquisition options for Acreage Holdings, Wana Brands, and Jetty Extracts. In late 2024, it acquired 84% of Acreage Holdings. If federal reform occurs (e.g., cannabis reclassified from Schedule I to Schedule III), Canopy could consolidate these assets.
This strategy could be a game changer, depending on U.S. regulatory developments in 2025–2026.
Management and Strategy
In January 2025, Luc Mongeau replaced David Klein as CEO. Mongeau brings over 25 years of experience from Mars and Weston Foods. CFO Judy Hong (ex-Goldman Sachs) has led effective cost-cutting initiatives.
The strategy focuses on three pillars:
Profitability in Canada by trimming underperforming segments
Expanding in international medical markets
Entering the U.S. market via Canopy USA
Industry Environment
Canada's legal cannabis market is oversupplied, with price compression and bankruptcies plaguing the sector. Nonetheless, market consolidation may benefit large players. The U.S. market offers immense potential, depending on reforms like the SAFE Banking Act or rescheduling under the Controlled Substances Act. Globally, medical cannabis legalization is expanding in Europe, LATAM, and parts of Asia.
Canopy remains a high-risk turnaround story, with potential upside tied to external developments. Its fundamentals are improving, but revenue remains flat and heavily dependent on future regulatory shifts.
2. Technical Analysis
CGC stock has been in a long-term downtrend since its 2021 peak (~$50). In December 2023, the company executed a 1:10 reverse stock split to maintain Nasdaq listing. Post-split, the stock opened 2024 at ~$9, fell 75% to ~$2.31 by year-end, and traded between $1.30–$1.60 in May 2025.
The 200-day moving average is around $3.2 (downward-sloping). However, the 50-day MA is at ~$1.17, with current prices above it. RSI sits at ~66 (bullish bias), and MACD is positive, indicating short-term upside momentum.
Support levels: $1.00 (psychological), $0.77 (52-week low). Resistance levels: $2.30 (recent peak), $3.50–4.00 (2022 levels), and $6 (2023 short-squeeze high).
Short-term technicals show bullish momentum, but long-term trend remains bearish. High volatility persists.
3. Peer Comparison
Metric (FY2024)
Canopy (CGC)
Tilray (TLRY)
Aurora (ACB)
Cronos (CRON)
Market Cap (May 2025)
~$350M
~$500M
~$240M
~$660M
Revenue
CAD 297M ↓11%
USD 789M ↑26%
CAD 270M ↑16%
USD 118M ↑35%
Net Income
-CAD 657M
-USD 222M
-CAD 55M
+USD 41M
Cash Reserves (2024)
CAD 203M
USD 408M
CAD 320M est.
USD 859M
Tilray is largest by revenue; diversified with beverages and wellness products.
Aurora focuses on global medical cannabis, showing improved EBITDA.
Cronos is the only peer posting net profit, with strong cash and Altria backing.
Canopy lags in profitability and cash reserves, but holds a broad brand portfolio and strategic positioning for the U.S. market.
4. Price Forecast & Sentiment
Analyst consensus is cautious. Only 2 analysts cover CGC, with a 12-month average target of $2.00, both giving sell ratings. Investor sentiment is weak, with ~10% short interest. However, speculative bursts can occur on legal reform news.
Scenarios (1–3 Years)
Bullish: U.S. reform passes; CGC integrates Canopy USA; stock reaches $5–$10.
Bearish: No legal progress; dilution continues; stock drops below $1.
Base case: Gradual improvement; stock ranges $2–$3, high volatility.
Conclusion
Canopy Growth is a high-risk, high-reward stock. Fundamentals are improving, but the turnaround is incomplete. Regulatory changes (esp. in the U.S.) are key. For risk-tolerant investors, CGC is essentially an option on cannabis legalization. Position sizing and constant monitoring are critical. A potential breakout above $2.30–$3.00 on volume could signal a trend shift. Until then, CGC remains speculative, with asymmetric upside if U.S. legal reform materializes.
Executive Summary
Canopy Growth Corporation (NASDAQ: CGC) is one of the most recognized players in the global cannabis industry, having experienced a dramatic rollercoaster ride over the past years. The stock peaked during the 2018 cannabis mania, only to lose over 99% of its value by now, reflecting sector-wide challenges and Canopy's financial struggles. This report offers an in-depth investment analysis for CGC over a 1–3 year timeframe, aimed at a risk-tolerant investor. The analysis is structured into four parts: fundamentals (financials, growth potential, management, industry environment), technical outlook (price charts, support-resistance levels, indicators), peer comparison, and price forecast (market sentiment and analysts' targets). Despite extreme risk, Canopy may offer significant upside under favorable conditions, making a deep understanding essential before any investment decision.
1. Fundamental Analysis
Financial Performance
In FY2024 (April 2023–March 2024), Canopy Growth reported revenue of CAD 297.1 million, an 11% YoY decline from CAD 333.3 million. However, net losses narrowed sharply: FY2024 net loss from continuing operations was CAD 483.7 million, compared to a staggering CAD 3.08 billion in FY2023. Total net loss attributable to shareholders stood at CAD 657.3 million, significantly improved from CAD 3.28 billion the year prior. Cost-cutting measures and the closure of unprofitable segments drove this turnaround, with the gross margin rising to 27%, up by 4600 basis points.
Operating loss in FY2024 was approximately CAD 229 million, while adjusted EBITDA loss dropped to CAD 59 million, a 72% improvement YoY. Cash reserves stood at CAD 203 million as of March 31, 2024, down from CAD 667 million the year before, indicating ongoing cash burn. The company refinanced debt proactively: no significant debt maturities until March 2026, after repaying a USD 100M term loan early.
Quarterly results in FY2024 showed progressive improvement: in Q3 (Oct–Dec 2024), operating loss was just CAD 24 million (down 61% YoY), and adjusted EBITDA loss was only CAD 3 million, nearing breakeven. Free cash flow in the quarter was -CAD 28 million, a 17% YoY improvement.
Despite reduced losses, Canopy remains unprofitable with negative operating and free cash flow. It also launched a USD 200 million ATM equity program in 2025, indicating potential shareholder dilution. However, the company completed its impairment phase, and asset write-downs in FY2024 were limited to CAD 66 million.
Growth Potential
Canopy has shifted focus from low-margin Canadian recreational cannabis to higher-margin medical cannabis, international markets, and vaporizer devices (via Storz & Bickel). In FY2024, Canadian medical cannabis revenue rose 10% to CAD 61 million, while the recreational segment declined. Storz & Bickel revenue grew 43% YoY in Q4.
International medical cannabis revenue grew 6% to CAD 41 million, driven by markets such as Australia, Germany, Poland, and the UK. The PEACE NATURALS brand became the leading cannabis brand in Israel.
The biggest growth opportunity lies in the U.S. market. Canopy cannot directly operate THC-based businesses in the U.S. due to federal prohibition, but it created Canopy USA, LLC, which holds acquisition options for Acreage Holdings, Wana Brands, and Jetty Extracts. In late 2024, it acquired 84% of Acreage Holdings. If federal reform occurs (e.g., cannabis reclassified from Schedule I to Schedule III), Canopy could consolidate these assets.
This strategy could be a game changer, depending on U.S. regulatory developments in 2025–2026.
Management and Strategy
In January 2025, Luc Mongeau replaced David Klein as CEO. Mongeau brings over 25 years of experience from Mars and Weston Foods. CFO Judy Hong (ex-Goldman Sachs) has led effective cost-cutting initiatives.
The strategy focuses on three pillars:
Profitability in Canada by trimming underperforming segments
Expanding in international medical markets
Entering the U.S. market via Canopy USA
Industry Environment
Canada's legal cannabis market is oversupplied, with price compression and bankruptcies plaguing the sector. Nonetheless, market consolidation may benefit large players. The U.S. market offers immense potential, depending on reforms like the SAFE Banking Act or rescheduling under the Controlled Substances Act. Globally, medical cannabis legalization is expanding in Europe, LATAM, and parts of Asia.
Canopy remains a high-risk turnaround story, with potential upside tied to external developments. Its fundamentals are improving, but revenue remains flat and heavily dependent on future regulatory shifts.
2. Technical Analysis
CGC stock has been in a long-term downtrend since its 2021 peak (~$50). In December 2023, the company executed a 1:10 reverse stock split to maintain Nasdaq listing. Post-split, the stock opened 2024 at ~$9, fell 75% to ~$2.31 by year-end, and traded between $1.30–$1.60 in May 2025.
The 200-day moving average is around $3.2 (downward-sloping). However, the 50-day MA is at ~$1.17, with current prices above it. RSI sits at ~66 (bullish bias), and MACD is positive, indicating short-term upside momentum.
Support levels: $1.00 (psychological), $0.77 (52-week low). Resistance levels: $2.30 (recent peak), $3.50–4.00 (2022 levels), and $6 (2023 short-squeeze high).
Short-term technicals show bullish momentum, but long-term trend remains bearish. High volatility persists.
3. Peer Comparison
Metric (FY2024)
Canopy (CGC)
Tilray (TLRY)
Aurora (ACB)
Cronos (CRON)
Market Cap (May 2025)
~$350M
~$500M
~$240M
~$660M
Revenue
CAD 297M ↓11%
USD 789M ↑26%
CAD 270M ↑16%
USD 118M ↑35%
Net Income
-CAD 657M
-USD 222M
-CAD 55M
+USD 41M
Cash Reserves (2024)
CAD 203M
USD 408M
CAD 320M est.
USD 859M
Tilray is largest by revenue; diversified with beverages and wellness products.
Aurora focuses on global medical cannabis, showing improved EBITDA.
Cronos is the only peer posting net profit, with strong cash and Altria backing.
Canopy lags in profitability and cash reserves, but holds a broad brand portfolio and strategic positioning for the U.S. market.
4. Price Forecast & Sentiment
Analyst consensus is cautious. Only 2 analysts cover CGC, with a 12-month average target of $2.00, both giving sell ratings. Investor sentiment is weak, with ~10% short interest. However, speculative bursts can occur on legal reform news.
Scenarios (1–3 Years)
Bullish: U.S. reform passes; CGC integrates Canopy USA; stock reaches $5–$10.
Bearish: No legal progress; dilution continues; stock drops below $1.
Base case: Gradual improvement; stock ranges $2–$3, high volatility.
Conclusion
Canopy Growth is a high-risk, high-reward stock. Fundamentals are improving, but the turnaround is incomplete. Regulatory changes (esp. in the U.S.) are key. For risk-tolerant investors, CGC is essentially an option on cannabis legalization. Position sizing and constant monitoring are critical. A potential breakout above $2.30–$3.00 on volume could signal a trend shift. Until then, CGC remains speculative, with asymmetric upside if U.S. legal reform materializes.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.